07:00 , Jun 11, 2012 |  BC Week In Review  |  Clinical News

CBP501: Preliminary Phase II data

Preliminary data from an open-label, international Phase II trial in 65 chemotherapy-naïve patients with unresectable MPM showed that 25 mg/m 2 IV CBP501 plus cisplatin and pemetrexed on day 1 of a 21-day cycle met...
00:47 , Jun 5, 2012 |  BC Extra  |  Clinical News

CanBas' CBP501 meets mesothelioma endpoint

CanBas Co. Ltd. (Tokyo:4575) said CBP501 plus cisplatin and pemetrexed met the primary endpoint of a progression-free survival rate greater than 55% at four months in a Phase II trial to treat malignant pleural mesothelioma...
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

CBP501 regulatory update

FDA granted Orphan Drug designation for CanBas' CBP501 to treat mesothelioma in combination with cisplatin and pemetrexed. CanBas expects to complete a Phase II trial evaluating the product plus cisplatin and pemetrexed for first-line treatment...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

CBP501: Completed Phase II enrollment

CanBas completed enrollment of 63 chemotherapy-naïve patients in an open-label, international Phase II trial comparing IV CBP501 plus cisplatin and pemetrexed vs. pemetrexed and cisplatin alone. Eli Lilly and Co. (NYSE:LLY, Indianapolis, Ind.) markets...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Clinical News

CBP501: Completed Phase II enrollment

CanBas completed enrollment of 192 patients in an open-label, international Phase II trial comparing 25 mg/m 2 IV CBP501 in combination with 500 mg/m 2 IV pemetrexed and 75 mg/m 2 IV cisplatin given on...
07:00 , Sep 28, 2009 |  BioCentury  |  Finance

Ebb & Flow

The pair of life sciences companies on IPO road shows may give investors and other companies clues on the opening of an IPO window. Profitable plasma-derived protein company Talecris Biotherapeutics Inc. may price this week,...
01:11 , Sep 22, 2009 |  BC Extra  |  Financial News

D. Western planning IPO

D. Western Therapeutics Institute Inc. (Nagoyashi, Japan) is planning to sell 3 million shares in an IPO. The offering is being underwritten by Nomura; Mitsubishi UFJ; Takagi; SBI Securities; Tokai Tokyo; Mizuho; Nikko Citigroup; Ichiyoshi;...
08:00 , Dec 15, 2008 |  BC Week In Review  |  Clinical News

CBP501: Phase II started

The partners began an open-label, international Phase II trial to evaluate cisplatin and pemetrexed with or with intravenous CBP501 in 65 patients. Takeda has exclusive rights to the product outside of the U.S., where the...
07:00 , Apr 14, 2008 |  BioCentury  |  Strategy

Takeda cancer deals

Takeda cancer deals Date Partner/Acquisition Description Terms 4/10/08 (A) Millennium (NASDAQ:MLNM) Takeda to acquire Millennium; deal is expected to strengthen its global oncology portfolio and expand its global gastrointestinal portfolio ~$8.8B in cash 3/31/08 Cell...
07:00 , Apr 14, 2008 |  BioCentury  |  Strategy

Cancer & GI pipeline

Cancer & GI pipeline Cancer Product Description Indication Status Originator Leuprorelin acetate (TAP-144SR) (A) 6-month depot formulation of leuprorelin, a luteinizing hormone releasing hormone(LHRH) agonist Prostate cancer Under review in EU Takeda Velcade (A)...